Hyderabad: Scientists at CSIR-Centre for Cellular and Molecular Biology (CCMB) have identified two compounds that prevent Candida albicans from changing into its infection-associated filamentous form without stopping its growth. A lead compound also significantly improved survival in mice with systemic Candida infection, offering a starting point for developing treatments.The study, from Dr Sriram Varahan’s laboratory and published in ACS Infectious Diseases, explores whether altering fungal behaviour could complement existing antifungal medicines. The compounds remain research candidates, with their safety, efficacy and therapeutic value requiring further investigation.Blocking the shape changeCandida albicans, described by researchers as a fungus present on human skin, can cause infections when it enters the bloodstream or internal organs. Its transition from rounded cells to long filaments makes it harder for the immune system to control.Earlier work from Varahan’s laboratory identified glycolysis, the pathway through which cells metabolise sugar, as a regulator of this transformation. Sugar metabolism functions both as an energy source and as a cellular switch influencing fungal shape.The team screened a library of small molecules targeting glycolysis. Two compounds inhibited filament formation while allowing the fungus to grow as rounded cells. The findings also identified pyruvate kinase, an enzyme involved in glycolysis, as a target for controlling fungal morphogenesis.Helping existing medicinesOne compound reduced biofilm formation in laboratory experiments. Biofilms shield the fungus from antifungal treatment. The compound also increased its sensitivity to fluconazole and amphotericin B, suggesting that targeting metabolic regulation could support existing therapies.The approach addresses a key concern: microbes can evolve resistance to drugs designed to kill them. With fungal pathogens increasing and relatively few antifungal drugs available, resistance threatens treatment options.Further testing needed“Our findings suggest that fungal disease-associated behaviour can be targeted without necessarily stopping fungal growth,” said Dhrumi Shah, the study’s first author.Varahan said further studies must establish how the compounds work, optimise their properties and assess their suitability for therapeutic development. The findings in mice are preclinical and do not establish effectiveness in humans.“The study does not establish these compounds as approved antifungal drugs; rather, it identifies promising candidates and a potential strategy for further development,” he said.
